Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations
Journal of Clinical Pharmacy and Therapeutics, 06/01/2012
Aoki T et al. – The successful treatment of ITP refractory to eltrombopag with romiplostim strongly suggests that the absence of cross–resistance between these two approved TPO receptor agonists and possible differences in mechanism of action. Further study of the mechanisms of action of TPO receptor agonists is called for along with further exploration of the potential of romiplostim in refractory ITP.